Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

CALIBER: a phase II randomized feasibility trial of chemoablation with mitomycin-C vs surgical management in low-risk non-muscle-invasive bladder cancer.

Mostafid AH, Porta N, Cresswell J, Griffiths TRL, Kelly JD, Penegar SR, Davenport K, McGrath JS, Campain N, Cooke P, Masood S, Knowles MA, Feber A, Knight A, Catto JWF, Lewis R, Hall E.

BJU Int. 2020 Mar 3. doi: 10.1111/bju.15038. [Epub ahead of print]

PMID:
32124514
2.

Surgeon-Team Separation in Robotic Theaters: A Qualitative Observational and Interview Study.

El-Hamamsy D, Walton TJ, Griffiths TRL, Anderson ES, Tincello DG.

Female Pelvic Med Reconstr Surg. 2020 Feb;26(2):86-91. doi: 10.1097/SPV.0000000000000829.

PMID:
31990793
3.

Radiofrequency-induced Thermo-chemotherapy Effect Versus a Second Course of Bacillus Calmette-Guérin or Institutional Standard in Patients with Recurrence of Non-muscle-invasive Bladder Cancer Following Induction or Maintenance Bacillus Calmette-Guérin Therapy (HYMN): A Phase III, Open-label, Randomised Controlled Trial.

Tan WS, Panchal A, Buckley L, Devall AJ, Loubière LS, Pope AM, Feneley MR, Cresswell J, Issa R, Mostafid H, Madaan S, Bhatt R, McGrath J, Sangar V, Griffiths TRL, Page T, Hodgson D, Datta SN, Billingham LJ, Kelly JD.

Eur Urol. 2019 Jan;75(1):63-71. doi: 10.1016/j.eururo.2018.09.005. Epub 2018 Sep 28.

PMID:
30274699
4.

Is Immediate Radical Cystectomy Necessary for All Patients with Non-Muscle-Invasive Micropapillary Bladder Cancer?

Jackson BL, Mohammed A, Mayer N, Dormer J, Griffiths TR.

Urol Int. 2016;96(1):32-8. doi: 10.1159/000375411. Epub 2015 Apr 29.

PMID:
25924623
5.

A green light for blue light … without single-dose chemotherapy.

Griffiths TR, Kockelbergh RC.

Eur Urol. 2014 Nov;66(5):872-3. doi: 10.1016/j.eururo.2014.07.006. Epub 2014 Jul 22. No abstract available.

PMID:
25063487
6.

Comet assay measures of DNA damage are predictive of bladder cancer cell treatment sensitivity in vitro and outcome in vivo.

Bowman KJ, Al-Moneef MM, Sherwood BT, Colquhoun AJ, Goddard JC, Griffiths TR, Payne D, Singh S, Butterworth PC, Khan MA, Summerton DJ, Steward WP, McKelvey-Martin VJ, McKeown SR, Kockelbergh RC, Mellon JK, Symonds RP, Jones GD.

Int J Cancer. 2014 Mar 1;134(5):1102-11. doi: 10.1002/ijc.28437. Epub 2013 Oct 8.

7.

Systematic review of adrenalectomy and lymph node dissection in locally advanced renal cell carcinoma.

Bekema HJ, MacLennan S, Imamura M, Lam TB, Stewart F, Scott N, MacLennan G, McClinton S, Griffiths TR, Skolarikos A, MacLennan SJ, Sylvester R, Ljungberg B, N'Dow J.

Eur Urol. 2013 Nov;64(5):799-810. doi: 10.1016/j.eururo.2013.04.033. Epub 2013 Apr 23. Review.

PMID:
23643550
8.

Current perspectives in bladder cancer management.

Griffiths TR; Action on Bladder Cancer.

Int J Clin Pract. 2013 May;67(5):435-48. doi: 10.1111/ijcp.12075. Epub 2012 Nov 9. Review.

9.

Inhibition of STAT signalling in bladder cancer by diindolylmethane: relevance to cell adhesion, migration and proliferation.

Sun Y, Cheng MK, Griffiths TR, Mellon JK, Kai B, Kriajevska M, Manson MM.

Curr Cancer Drug Targets. 2013 Jan;13(1):57-68.

PMID:
22920439
10.

Systematic review of perioperative and quality-of-life outcomes following surgical management of localised renal cancer.

MacLennan S, Imamura M, Lapitan MC, Omar MI, Lam TB, Hilvano-Cabungcal AM, Royle P, Stewart F, MacLennan G, MacLennan SJ, Dahm P, Canfield SE, McClinton S, Griffiths TR, Ljungberg B, N'Dow J; UCAN Systematic Review Reference Group; EAU Renal Cancer Guideline Panel.

Eur Urol. 2012 Dec;62(6):1097-117. doi: 10.1016/j.eururo.2012.07.028. Epub 2012 Jul 20. Review.

PMID:
22841673
11.

Corrigendum to "Systematic Review of Oncological Outcomes Following Surgical Management of Localised Renal Cancer" [Eur Urol 2012;61:972-93].

MacLennan S, Imamura M, Lapitan MC, Omar MI, Lam TB, Hilvano-Cabungcal AM, Royle P, Stewart F, MacLennan G, MacLennan SJ, Canfield SE, McClinton S, Griffiths TR, Ljungberg B, N'Dow J; UCAN Systematic Review Reference Group.

Eur Urol. 2012 Jul;62(1):193. doi: 10.1016/j.eururo.2012.04.003. Epub 2012 Apr 12. No abstract available.

PMID:
27989305
12.

DFT models of molecular species in carbonate molten salts.

Carper WR, Wahlbeck PG, Griffiths TR.

J Phys Chem B. 2012 May 10;116(18):5559-67. doi: 10.1021/jp3016694. Epub 2012 Apr 30.

PMID:
22512323
13.

Systematic review of oncological outcomes following surgical management of localised renal cancer.

MacLennan S, Imamura M, Lapitan MC, Omar MI, Lam TB, Hilvano-Cabungcal AM, Royle P, Stewart F, MacLennan G, MacLennan SJ, Canfield SE, McClinton S, Griffiths TR, Ljungberg B, N'Dow J; UCAN Systematic Review Reference Group; EAU Renal Cancer Guideline Panel.

Eur Urol. 2012 May;61(5):972-93. doi: 10.1016/j.eururo.2012.02.039. Epub 2012 Feb 25. Review. Erratum in: Eur Urol. 2012 Jul;62(1):193.

PMID:
22405593
14.

Changing antibiotic prophylaxis for transrectal ultrasound-guided prostate biopsies: are we putting our patients at risk?

Stephenson JA, Green CA, Bukhari SS, Griffiths TR.

BJU Int. 2011 Aug;108(4):E155. doi: 10.1111/j.1464-410X.2011.10536_1.x. No abstract available.

15.

Urological cancer care pathways: development and use in the context of systematic reviews and clinical practice guidelines.

Maclennan SJ, Maclennan SJ, Imamura M, Omar MI, Vale L, Lam T, Royle P, Royle J, Swami S, Pickard R, McClinton S, Griffiths TR, Dahm P, N'dow J; UCAN Care Pathway Development Group.

World J Urol. 2011 Jun;29(3):291-301. doi: 10.1007/s00345-011-0660-9. Epub 2011 Feb 25. Review.

16.

Photodynamic diagnosis of bladder cancer compared with white light cystoscopy: Systematic review and meta-analysis.

Mowatt G, N'Dow J, Vale L, Nabi G, Boachie C, Cook JA, Fraser C, Griffiths TR; Aberdeen Technology Assessment Review (TAR) Group.

Int J Technol Assess Health Care. 2011 Jan;27(1):3-10. doi: 10.1017/S0266462310001364. Epub 2011 Jan 25. Review.

PMID:
21262078
17.

Management of the distal ureter during nephroureterectomy for upper urinary tract transitional cell carcinoma: a review.

Gkougkousis EG, Mellon JK, Griffiths TR.

Urol Int. 2010;85(3):249-56. doi: 10.1159/000302715. Epub 2010 Mar 24. Review.

18.

Is the role of intravesical bacillus Calmette-Guérin in non-muscle-invasive bladder cancer changing?

Ayres BE, Griffiths TR, Persad RA.

BJU Int. 2010 Feb;105 Suppl 2:8-13. doi: 10.1111/j.1464-410X.2009.09151.x. Review. No abstract available.

19.

The role of hexylaminolaevulinate in the diagnosis and follow-up of non-muscle-invasive bladder cancer.

Bunce C, Ayres BE, Griffiths TR, Mostafid H, Kelly J, Persad R, Kockelbergh R.

BJU Int. 2010 Feb;105 Suppl 2:2-7. doi: 10.1111/j.1464-410X.2009.09150.x. Review. No abstract available.

20.

Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of bladder cancer.

Mowatt G, Zhu S, Kilonzo M, Boachie C, Fraser C, Griffiths TR, N'Dow J, Nabi G, Cook J, Vale L.

Health Technol Assess. 2010 Jan;14(4):1-331, iii-iv. doi: 10.3310/hta14040. Review.

21.

SIP1 protein protects cells from DNA damage-induced apoptosis and has independent prognostic value in bladder cancer.

Sayan AE, Griffiths TR, Pal R, Browne GJ, Ruddick A, Yagci T, Edwards R, Mayer NJ, Qazi H, Goyal S, Fernandez S, Straatman K, Jones GD, Bowman KJ, Colquhoun A, Mellon JK, Kriajevska M, Tulchinsky E.

Proc Natl Acad Sci U S A. 2009 Sep 1;106(35):14884-9. doi: 10.1073/pnas.0902042106. Epub 2009 Aug 17.

22.

Lapatinib, a dual inhibitor of ErbB-1/-2 receptors, enhances effects of combination chemotherapy in bladder cancer cells.

McHugh LA, Sayan AE, Mejlvang J, Griffiths TR, Sun Y, Manson MM, Tulchinsky E, Mellon JK, Kriajevska M.

Int J Oncol. 2009 Apr;34(4):1155-63.

PMID:
19287975
23.

Editorial comment on: Thirty-day mortality after nephrectomy: clinical implications for informed consent.

Griffiths TR.

Eur Urol. 2009 Dec;56(6):1004-5. doi: 10.1016/j.eururo.2008.11.025. Epub 2008 Nov 25. No abstract available.

PMID:
19054606
24.

An improvised delivery system for irrigation.

Walton TJ, Heads S, Parkinson RJ, Griffiths TR.

Ann R Coll Surg Engl. 2008 Jul;90(5):429-30. No abstract available.

25.

Metastasis-associated protein S100A4: spotlight on its role in cell migration.

Tarabykina S, Griffiths TR, Tulchinsky E, Mellon JK, Bronstein IB, Kriajevska M.

Curr Cancer Drug Targets. 2007 May;7(3):217-28. Review.

PMID:
17504119
26.

The first semen analysis after vasectomy: timing and definition of success.

Bodiwala D, Jeyarajah S, Terry TR, Griffiths TR.

BJU Int. 2007 Apr;99(4):727-8. No abstract available.

27.
28.

Epidermal growth factor receptor status predicts local response to radical radiotherapy in muscle-invasive bladder cancer.

Colquhoun AJ, Sundar S, Rajjayabun PH, Griffiths TR, Symonds RP, Mellon JK.

Clin Oncol (R Coll Radiol). 2006 Nov;18(9):702-9.

PMID:
17100158
29.

Oxidative stress and cyclooxygenase activity in prostate carcinogenesis: targets for chemopreventive strategies.

Pathak SK, Sharma RA, Steward WP, Mellon JK, Griffiths TR, Gescher AJ.

Eur J Cancer. 2005 Jan;41(1):61-70. Review.

PMID:
15617991
30.

A prospective audit of hypospadias correction in a regional paediatric surgery centre.

Heer R, Dorkin TJ, Byrne RL, Griffiths TR, Rangecroft L.

Eur J Pediatr Surg. 2004 Oct;14(5):328-32.

PMID:
15543482
31.

T1G3 transitional cell carcinoma of the bladder: recurrence, progression and survival.

McHugh LA, Griffiths TR.

BJU Int. 2004 Jul;94(1):193. No abstract available.

32.

Evolving immunotherapeutic strategies in bladder and renal cancer.

Griffiths TR, Mellon JK.

Postgrad Med J. 2004 Jun;80(944):320-7. Review.

33.

Tyrosine kinase inhibitors of the epidermal growth factor receptor as adjuncts to systemic chemotherapy for muscle-invasive bladder cancer.

McHugh LA, Griffiths TR, Kriajevska M, Symonds RP, Mellon JK.

Urology. 2004 Apr;63(4):619-24. Review. No abstract available.

PMID:
15072863
34.

Cytologic analysis of ureteral washings is informative in patients with grade 2 upper tract TCC considering endoscopic treatment.

Skolarikos A, Griffiths TR, Powell PH, Thomas DJ, Neal DE, Kelly JD.

Urology. 2003 Jun;61(6):1146-50.

PMID:
12809884
35.

Treatment of carcinoma in situ with intravesical bacillus Calmette-Guerin without maintenance.

Griffiths TR, Charlton M, Neal DE, Powell PH.

J Urol. 2002 Jun;167(6):2408-12.

PMID:
11992047
36.

Distribution of lymphocytes of the alpha(E)beta(7) phenotype and E-cadherin in normal human urothelium and bladder carcinomas.

Cresswell J, Robertson H, Neal DE, Griffiths TR, Kirby JA.

Clin Exp Immunol. 2001 Dec;126(3):397-402.

37.

Combined p21WAF1/CIP1 and p53 overexpression predict improved survival in muscle-invasive bladder cancer treated by radical radiotherapy.

Qureshi KN, Griffiths TR, Robinson MC, Marsh C, Roberts JT, Lunec J, Neal DE, Mellon JK.

Int J Radiat Oncol Biol Phys. 2001 Dec 1;51(5):1234-40.

PMID:
11728682
38.

Human papillomavirus and urological tumours: II. Role in bladder, prostate, renal and testicular cancer.

Griffiths TR, Mellon JK.

BJU Int. 2000 Jan;85(2):211-7. Review. No abstract available.

39.

TP53 accumulation predicts improved survival in patients resistant to systemic cisplatin-based chemotherapy for muscle-invasive bladder cancer.

Qureshi KN, Griffiths TR, Robinson MC, Marsh C, Roberts JT, Hall RR, Lunec J, Neal DE.

Clin Cancer Res. 1999 Nov;5(11):3500-7.

40.

Human papillomavirus and urological tumours: I. Basic science and role in penile cancer.

Griffiths TR, Mellon JK.

BJU Int. 1999 Sep;84(5):579-86. Review. No abstract available.

PMID:
10510097
41.

Bladder cancer immunogenicity: expression of CD80 and CD86 is insufficient to allow primary CD4+ T cell activation in vitro.

Pettit SJ, Ali S, O'Flaherty E, Griffiths TR, Neal DE, Kirby JA.

Clin Exp Immunol. 1999 Apr;116(1):48-56.

43.

Localized prostate cancer: early intervention or expectant therapy?

Griffiths TR, Neal DE.

J R Soc Med. 1997 Dec;90(12):665-9. Review. No abstract available.

44.

Bladder cancer.

Leung HY, Griffiths TR, Neal DE.

Postgrad Med J. 1996 Dec;72(854):719-24. Review.

45.

Cell adhesion molecules in bladder cancer: soluble serum E-cadherin correlates with predictors of recurrence.

Griffiths TR, Brotherick I, Bishop RI, White MD, McKenna DM, Horne CH, Shenton BK, Neal DE, Mellon JK.

Br J Cancer. 1996 Aug;74(4):579-84.

46.

P53 and ploidy assessed by flow cytometry in bladder washings.

Griffiths TR, Mellon JK, Pyle GA, Shenton BK, Neal DE.

Br J Urol. 1995 Nov;76(5):575-9.

PMID:
8535675
47.

A new unifying theory for the initiation of ageing mechanisms and processes.

Griffiths TR.

Mech Ageing Dev. 1973 Oct-Nov;2(4):295-307. No abstract available.

PMID:
4778851

Supplemental Content

Loading ...
Support Center